Hepatitis D Latest Advances

Corrigendum to 'Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort' [JHEP Reports (2026) 19;8(8):101898].

Journal: JHEP reports : innovation in hepatology

Published: September 03, 2026

Genome organization and packaging, mutation impacts and quasi-periodic patterns in viral genomes.

Journal: Journal of biomolecular structure & dynamics

Published: September 02, 2026

Natural immune escape mutations in the envelope proteins of hepatitis B virus (HBV) regulate the assembly and infectivity of human hepatitis delta virus (HDV).

Journal: Journal of virology

Published: September 01, 2026

Corrigendum to "Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D" [JHEP Reports 4 (2022) 100547].

Journal: JHEP reports : innovation in hepatology

Published: August 25, 2026

Ensuring pragmatic and equitable paths forward for hepatitis B virus infection elimination in Latin America.

Journal: Expert review of anti-infective therapy

Published: August 24, 2026

First treatment approved for chronic hepatitis delta virus infection.

Journal: The American journal of nursing

Published: August 20, 2026

Bulevirtide approved by FDA for chronic hepatitis D.

Journal: The Lancet. Microbe

Published: August 12, 2026

Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation.

Journal: The Annals of pharmacotherapy

Published: August 09, 2026

An Exploratory Evaluation of the Present Prevalence of Hepatitis D Infection in Selected Populations from Venezuela, Contrasted with Past Studies in the Country.

Journal: Microorganisms

Published: July 15, 2026

Pegylated interferon for chronic hepatitis delta: does it still have a role in the bulevirtide era?

Journal: Revista espanola de enfermedades digestivas

Published: July 13, 2026

Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.

Journal: Journal of virology

Published: July 13, 2026

Corrigendum to: "HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers" [JHEP Reports 5 (2023) 100842].

Journal: JHEP reports : innovation in hepatology

Published: July 08, 2026

Hepatitis D Latest Advances

Find the Latest Research About Hepatitis D

Corrigendum to 'Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort' [JHEP Reports (2026) 19;8(8):101898].

Corrigendum to 'Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort' [JHEP Reports (2026) 19;8(8):101898].

Genome organization and packaging, mutation impacts and quasi-periodic patterns in viral genomes.

Genome organization and packaging, mutation impacts and quasi-periodic patterns in viral genomes.

Natural immune escape mutations in the envelope proteins of hepatitis B virus (HBV) regulate the assembly and infectivity of human hepatitis delta virus (HDV).

Natural immune escape mutations in the envelope proteins of hepatitis B virus (HBV) regulate the assembly and infectivity of human hepatitis delta virus (HDV).

Corrigendum to "Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D" [JHEP Reports 4 (2022) 100547].

Corrigendum to "Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D" [JHEP Reports 4 (2022) 100547].

Ensuring pragmatic and equitable paths forward for hepatitis B virus infection elimination in Latin America.

Ensuring pragmatic and equitable paths forward for hepatitis B virus infection elimination in Latin America.

First treatment approved for chronic hepatitis delta virus infection.

First treatment approved for chronic hepatitis delta virus infection.

Bulevirtide approved by FDA for chronic hepatitis D.

Bulevirtide approved by FDA for chronic hepatitis D.

Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation.

Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation.

An Exploratory Evaluation of the Present Prevalence of Hepatitis D Infection in Selected Populations from Venezuela, Contrasted with Past Studies in the Country.

An Exploratory Evaluation of the Present Prevalence of Hepatitis D Infection in Selected Populations from Venezuela, Contrasted with Past Studies in the Country.

Pegylated interferon for chronic hepatitis delta: does it still have a role in the bulevirtide era?

Pegylated interferon for chronic hepatitis delta: does it still have a role in the bulevirtide era?

Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.

Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.

Corrigendum to: "HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers" [JHEP Reports 5 (2023) 100842].

Corrigendum to: "HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers" [JHEP Reports 5 (2023) 100842].